Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
Furst
D E
DE
University of California at Los Angeles, Los Angeles, USA. defurst@mednet.ucla.edu
Keystone
E C
EC
Fleischmann
R
R
Mease
P
P
Breedveld
F C
FC
Smolen
J S
JS
Kalden
J R
JR
Braun
J
J
Bresnihan
B
B
Burmester
G R
GR
De Benedetti
F
F
Dörner
T
T
Emery
P
P
Gibofsky
A
A
Kavanaugh
A
A
Kirkham
B
B
Schiff
M H
MH
Sieper
J
J
Singer
N
N
Van Riel
P L C M
PL
Weinblatt
M E
ME
Weisman
M H
MH
Winthrop
K
K
D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000069594:Abatacept; C502936:tocilizumab